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N-acetyl transferase 1: two polymorphisms in coding
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Summary Increased cancer risk has been associated with functional polymorphisms that occur within the genes coding for the N-
acetyltransferase enzymes NAT1 and NAT2. We detected two NAT1 polymorphisms in colorectal cancer patients by heteroduplex analysis.
DNA sequencing revealed the wild-type sequence (NAT1*4) and two single base substitutions at adjacent positions 999 bp (C to T, NAT1*14)
and 1000 bp (G to A, NAT1*15) of the gene, changing Arg187 to a stop codon and Arg187 to Gin respectively. NAT1 alleles NAT1*4 (0.98) and
NAT1*15 (0.02) were present at a similar frequency in patients with colorectal cancer (n = 260) and in a Scottish control group (n = 323). The
third allele, NAT1*14, was present only in the colorectal cancer group at a frequency of 0.006. NAT1 genotype NAT1*4/ NAT1*15 was
significantly less frequent in individuals that had a slow NAT2 genotype. This was observed in both cancer and control groups and suggests
that this association was unrelated to cancer risk. We conclude that polymorphisms within the coding region of the NAT1 gene are infrequent
and do not appear to have an independent association with colorectal cancer risk. However, the relationship between NAT1 and NAT2
polymorphisms appears non-random, suggesting a linkage between these enzymes.
Keywords: colorectal cancer, N-acetyltransferase 1, polymorphism, cancer risk
The N-acetyl transferases (NAT1 and NAT2, also known as AACl
and AAC2) are xenobiotic enzymes that metabolize inhaled or
ingested carcinogenic compounds, including arylamine and
heterocyclic amine compounds present in cigarette smoke (Vineis,
1994) and in cooked food (Sugimura et al, 1994). Both NATI and
NAT2 genes are known to reside on chromosome 8p (Blum et al,
1990; Franke et al, 1994). Polymorphic forms of NAT genes have
the potential to affect an individual's response to carcinogens
thereby influencing cancer risk. Polymorphisms of NAT2 that
result in slow acetylation ofmetabolites have been associated with
bladder cancer (Risch et al, 1995) and, conversely, fast acetylators
may be more common in colorectal cancer and some types of
breast cancer (Lang et al, 1986; Agundez et al, 1995). However
these associations are weak and are not supported by all studies
(Bell et al, 1995a; Hubbard et al, 1997).
A potentially confounding factor in these assessments is the
contribution of NATI, a closely related enzyme that shares some
substrate specificity with NAT2 (Hein et al, 1992), which is
expressed at higher levels than NAT2 in colonic epithelial cells
(Turesky et al, 1991). Recent studies have shown that NATI is also
polymorphic and 15 variants have been detected in animal and
human gene sequences (Vatsis and Weber, 1993; Weber and Vatsis,
1993; Grant et al, 1997). One variant, the NAT1*10 allele, is more
frequent in patients with bladder and colon cancer (Bell et al,
1995a). The NAT1*10 allele contains a single base substitution in
the polyadenylation signal in the 3' untranslated region ofthe gene
which results in increased NATI enzyme activity (Bell et al, 1995b)
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and raises the possibility that the NATI enzyme may function as a
carcinogen activator in some individuals. We examined the NATI
gene coding sequence and present data on two polymorphisms
within the coding sequence ofthe NATI gene, and asimple method
for the detection ofthese polymorphisms in DNA samples.
MATERIALS AND METHODS
Study cases
Peripheral blood and colorectal cancer tissue was collected from a
consecutive series of operable colorectal cancer patients after
surgery in three local hospitals between 1988 and 1993 (Edinburgh
Royal Infirmary, Edinburgh, UK; Western General Hospital,
Edinburgh, UK; St Johns Hospital, Livingstone, UK). Age at
diagnosis ranged between 20 and 95 years and cases were
equally distributed for gender. Cancer diagnosis was confirmed
histopathologically and were classified according to Dukes' stages
(A, B, C) and according to position ofcancer in the colon as either
right (caecum, ascending and transverse) or left (sigmoid,
descending and rectum) sides. A random control cohort was
provided by Dr Peng Lee Yap, Scottish National Blood
Transfusion Service, Edinburgh, UK. Samples ofperipheral blood
were obtained from healthy individuals attending routine occupa-
tional screening, with approximately equal male to female ratios
and distributed over the age range 18-65 years. Both cancer and
control groups were from the same Caucasian population base.
Collection of blood from cancer patients has been given local
ethical approval. DNA was extracted from peripheral blood
lymphocytes using standard methods (Cantlay et al, 1995).
The polymorphic status of the N-acetyltransferase 2 gene in
these cancer and control groups was determined previously
(Hubbard et al, 1997).
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Figure 1 Heteroduplex analysis of three colorectal cancer DNAs (tracks
3-5). The wild type banding pattern is shown in track 3 and the variant
banding pattern in tracks 4 and 5. Track 1 contains a 1-kb molecular weight
marker (Gibco BRL, UK) and track 2 contains a positive control for
heteroduplex (FMC Bioproducts, UK)
NAT1
The NATI gene was examined for polymorphism using primers
designed from the published human gene sequence (Blum et al,
1990). The primer pair P1 [5'-ACG GAA GAG AAT GGA TTC
TGG TAT-3', sense; nucleotides 897-920] and P2 [5' GGG TCT
GCA AGG AAC AAA ATG-3', antisense; nucleotides 1122-
1102] generated a 225-bp NATI specific fragment that showed
polymorphism on heteroduplex analysis.
The polymerase chain reaction was performed on a Hybaid
Omnigene thermal cycler using 200 ng ofgenomic DNA, 80 ng of
each primer, 200 mM dNTPs (Pharmacia, UK), x 1 polymerase
buffer (Promega, UK), 1.5 mm magnesium chloride, 4% dimethyl
sulphoxide (DMSO) and 1 unit of Taq polymerase (Promega, UK)
in a total volume of 50 ,l. Main cycling parameters were: 38
cycles of94°C for 20 s, 62.50C for 20 s and 720C for 15 s.
Heteroduplex analysis
Polymorphic alleles were identified by heteroduplex analysis.
Duplexes were formed by denaturation of 20gl of PCR product
at 95°C for 3 min, followed by cooling to 37°C over 30 min.
Samples were separated by shape and size on x 1 MDE polyacryl-
amide gels (Pharmacia-Hoeffer, UK), in x 0.6 Tris borate buffer
(NBL Gene Sciences, UK) containing 18% (w/v) urea, at 600 V
for 16 h. DNA present in gels was silver stained using the
following protocol: 10% ethanol for 10 min, 1% nitric acid
for 10 min, distilled water for 5 min, 0.24% (w/v) silver nitrate for
20 min, distilled water rinse for 10 s. Silver staining was
developed in two changes of 230 mm sodium carbonate and
0.05% formaldehyde (37%) and fixed in 0.1 M citric acid.
DNA sequencing
Samples with variant and invariant banding patterns were DNA
sequenced using the Sequenase protocol (Amersham Life
Sciences, UK). NATl-specific sequences were PCR amplified as
above, except for substitution of the antisense primer for an iden-
tical biotinylated primer. Amplified DNA was purified using the
Wizard DNA clean-up system (Promega, UK) and denatured using
streptavidin-coated superparamagnetic beads (Dynabeads, Dynal,
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Figure 2 Sequence analysis of a 225-bp fragment of the NAT1 gene. The
sequence corresponding to the wild-type pattern of heteroduplex is shown in
sample 1, a single base change at position 1000-bp, G to A, is shown in
sample 2 and at position 999 bp, C to T, in sample 3. Polymorphic bands are
indicated by an arrow
Norway), both according to manufacturers' instructions. The sense
strand was sequenced according to the Sequenase protocol using
0.5 pmol of primer P2 and 5 ,uCi of [a-35S]dATP. Samples were
denatured at 950C for 3 min, then electrophoresed on 6% dena-
turing polyacrylamide gels at 65 W for 2 h. Gels were fixed in
10% methanol, 10% acetic acid and then dried under vacuum for
2 h. Dried gels were exposed to X-Omat radiographic film
overnight and developed automatically in a X2 Hyperprocessor
(Amersham, UK). The DNA sequence was determined manually.
Data analysis
Allele frequencies for each group were calculated and genotype
distribution forcancers and controls were tested forgoodness offit
with the Hardy-Weinberg equilibrium. Any deviations from this
equilibrium were calculated using a chi-squared test. Genotype
distributions of the colon cancer and control groups were
compared using thechi-squared test incorporating Yates continuity
correction, and P-values less than 0.05 were considered to be
significant.
RESULTS
Detection and identification of NAT1 coding sequence
polymorphisms
Using NATI specific primers, a 225-bp DNA fragment was
amplified from 260 colon cancer patient DNAs, and heteroduplex
analysis produced a common single band pattern (allele NAT1*4)
and a variant pattern of two or three bands on silver stained
polyacrylamide gels (Figure 1). DNA sequencing of the variant
samples identified two separate base changes, G to A at position
1000 bp (allele NATl*15) or C to T at position 999 bp (allele
NAT1*14) ofthe NAT1 gene (Figure 2). These base changes result
in an amino acid substitution Arg'87-Gln ( NATi *15) and a stop
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Table 1 Distribution of NAT1 allele frequency in 260 colorectal cancer
cases and 323 control samples
NATI allele frequency
NAT1*4 NAT1*15 NAT1*14
Cancer group 0.975 0.019 0.006
Control group 0.98 0.02 0
Table 2 Distribution of NAT1 genotype with clinical features of colorectal
cancers in 260 colorectal cancer cases and 323 control samples
NAT1 genotype
NAT1*4/*4 NAT1*4/*15 NAT1*4/*14 X2 analysis
Table 3 Distribution of functional polymorphisms in NAT1 and NAT2 genes
in colorectal cancers and the control group
NAT1 genotype
NAT1*41*4 NAT1*41*15 NAT1*4/*14
Colorectal cancergroup
NAT2 genotype
Predicted fast 81 (91) 8 (9) 0
Predicted slow 151 (96.8) 2 (1.3) 3 (1.9)
Controlgroup
NAT2 genotype
Predicted fast 82 (88.2) 11 (11.8) 0
Predicted slow 123 (99.2) 1 (0.8) 0
Numbers in parentheses are percentages.
Cancer group 247 10 3
Control group 311 12 0
Cancergroup only
Sex
Male
Female
Side
Right
Left
Age at presentation
(years)
<70
.70
Dukes' stage
A
B
C
133 3 1
114 7 2
86 5 2
161 5 1
122 5 1
125 5 2
28
114
105
6
3
0
3
0
X2 analyses of 2 x 3 and 3 x 3 contingency tables were calc
Yates correction.
codon Arg'87-stop (NAT1*14) and were named in a
the nomenclature ofVatsis et al (1995). DNA sequc
22 samples with a single heteroduplex band showe
wild-type sequence.
NAT1 polymorphism and colorectal cancer
NATI allele frequencies and the distribution of NA
260 cancers and 323 controls are shown in Tables
alleles NAT1*4 and NATI*15 occurred with simila
the cancer and the control groups, but allele NAT1'
at low frequency (0.006) and found only in the ca
each group, the distribution of genotype was con
Hardy-Weinberg equilibrium (colon cancers X2 =
P . 0.5; control group X2 = 0.12, d.f. = 1, P . 0.5
genotype frequencies are constant and not affected 1
selection within each group. Despite the pres
NAT1*14 in the cancer group, the distribution ofge
control and cancer groups was not significantly
squared using Yates correction = 1.84, d.f. = 2, P
cates no selection bias for genotype with colore(
found no difference in NAT1 genotype distribution
onset, site and Dukes' stage in the cancer group (Ta
X2= 1.84, P>0.3
X2= 1.14, P.0.3
X2 = 0.679, P> 0.5
The NAT2 genotype of 217 control and 245 colorectal cancer
samples was determined previously (Hubbard et al, 1997). The
NATI genotype NATl*4/NAT1*15 was significantly less frequent
in individuals who had a slow NAT2 genotype (Table 3). This was
observed in both cancer (X2 = 7.02, 2 d.f., P < 0.05) and control
(X2 = 9.8, 1 d.f., P <0.01) groups and was unrelated to cancer risk.
DISCUSSION
We have identified two polymorphisms within the protein coding
(2 = 0.072, P> 0.5 region of the NAT1 gene. One polymorphism results in an amino
acid substitution at codon 187 and is present at a similar frequency
in colorectal cancer patients and in control samples. The second
polymorphism is present at low frequency and was detected only
X2 = 1.8, P.0.5 in the colorectal cancer group. This introduces a stop codon at
position 187. Although neither polymorphism is associated with
:ulated using any clinically defined subgroup of colorectal cancer (sex, site of
cancer, age of onset and Dukes' stage), the relationship between
NATI and NAT2 polymorphisms was non-random in both control
and cancer groups. This suggests that combined genotypes of
Lccordance with NATI and NAT2 do not cooperate in cancer risk and indicates
ence analysis of either a genetic linkage or a relationship between these enzymes.
-d the predicted Other polymorphisms have been found in the NAT1 gene that
cluster around the 3' untranslated region of the gene (Vatsis and
Weber, 1993), one of which is thought to affect enzyme activity
(Bell et al, 1995b). It is not known whethervarious polymorphisms
in NATI are linked or what effect multiple polymorphisms may
MTl genotype in have on enzyme activity. Biochemical variation in NATI enzyme
1 and 2. NAT1 activity has been detected when individual patients were tested
r frequencies in using the substrate P-aminobenzoic acid (Vatsis and Weber, 1993;
*14 was present Vatsis et al, 1995), but polymorphisms identified in the polyadeny-
ncer group. For lation region ofthe NATI gene (Vatsis and Weber, 1993; Bell et al,
sistent with the 1995a), have failed to account for some slow acetylators, thereby
0.17, d.f. = 2, indicating the presence of additional factors influencing NAT1
5) implying that enzyme activity. The two polymorphisms described in this report
by mutation and occur within the coding sequence and may reduce enzyme activity
ence of allele or alter enzyme specificity. High NATI activity has been previ-
notype between ously associated with an increased risk of bladder and colorectal
different (chi- cancer (Badawi et al, 1995; Bell et al, 1995a), suggesting that
> 0.3) and indi- NATI may play an activation role in carcinogenesis. The precise
ctal cancer. We mechanisms that may be involved remain unclear. Larger study
with sex, age of groups may help to clarify the precise nature ofcancer risk associ-
ble 2). ated with these polymorphisms, particularly when mutant alleles
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are infrequent, and allow analysis of multiple xenobiotic enzyme
polymorphisms. However, infrequent alleles are likely to have
only a small influence on overall risk.
The substitution of the hydrophilic amino acid glycine for argi-
nine (allele NAT1*15) at codon 187 may affect enzyme activity
and specificity, as this domain is thought to be critical for deter-
mining substrate specificity (Dupret et al, 1994). The introduction
of a stop codon (allele NATI*14) at codon'57, results in the loss of
104 amino acids from the C-terminus ofNAT1. Although the puta-
tive active site remains with the truncated protein (residues
47-l11), the C-terminus amino acids (residues 211-250) play an
important role in enzyme stability, and residues 112-210 deter-
mine specificity (Dupret et al, 1994). Therefore, this polymor-
phism is likely to severely impair or abrogate enzyme function.
However, there may only be small differences in enzyme activity
between genotypes NATI*4/*4, NATI*4/*14 and NATI*4/*15.
This has yet to be demonstrated biochemically. It is interesting to
note that allele NAT1*14 was found only in colon cancer patients.
The NAT1 genotype NATI*4/NAT1*15 was less frequent than
expected, if random distribution is assumed, in individuals with a
slow NAT2 genotype in both the control and the cancer groups.
This may represent genetic linkage between NATI and NAT2,
which are closely related and have overlapping substrate speci-
ficity (Turesky et al, 1991). This linkage may confound studies of
NAT1 and NAT2 polymorphism with disease susceptibility.
Polymorphisms within the coding region of the NAT1 gene are
infrequent and do not appear to be independently associated with
colorectal cancer risk. However, these alleles are likely to affect
enzyme activity and may be in linkage with particular alleles ofthe
NAT2 gene.
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